Cite
HARVARD Citation
Yang, C. et al. (2022). Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial. Therapeutic advances in medical oncology. p. . [Online].